No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BBIO BridgeBio Pharma
- 26.190
- +0.260+1.00%
Close Jul 19 16:00 ET
4.90BMarket Cap-8108P/E (TTM)
26.590High25.870Low1.02MVolume26.100Open25.930Pre Close26.77MTurnover0.84%Turnover RatioLossP/E (Static)187.13MShares44.32052wk High-4.67P/B3.17BFloat Cap21.62052wk Low--Dividend TTM121.21MShs Float73.500Historical High--Div YieldTTM2.78%Amplitude4.980Historical Low26.222Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Press Release: BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, t
BridgeBio Pharma Price Target Maintained With a $70.00/Share by Cantor Fitzgerald
BridgeBio Pharma Price Target Maintained With a $70.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on BridgeBio Pharma, Maintains $70 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates BridgeBio Pharma with a Overweight and maintains $70 price target.
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
J.P. Morgan analyst Anupam Rama maintains $BridgeBio Pharma(BBIO.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.8% and a total average return of 5.0% over the
Buy Rating Affirmed for BridgeBio Pharma Amid Market Overreaction and Promising Long-Term Prospects
Comments
Morning Movers
Gapping up
$Starbucks(SBUX.US$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$Novo-Nordisk A/S(NVO.US$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
Gapping up
$Starbucks(SBUX.US$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$Novo-Nordisk A/S(NVO.US$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
17
Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF(XBI.US$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the $S&P 500 Index(.SPX.US$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...
29
1
$BridgeBio Pharma(BBIO.US$ BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
2 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
2 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg